Jaguar Health, Inc. Form 8-K/A Summary
Business Context and Reporting Period
This filing is an Amendment No. 1 to a Current Report on Form 8-K filed by Jaguar Health, Inc. (JAGX) on January 12, 2026. The amendment corrects scrivener's errors regarding the execution and closing dates of a securities transaction, which are now confirmed as January 6, 2026. The company is a Delaware corporation with principal executive offices in San Francisco, California.
Key Financial Metrics and Transaction Details
- Debt Issuance: The Company issued unsecured promissory notes with an aggregate principal amount of $350,000 to two accredited investors.
- Interest Rate: The notes bear interest at 6% per annum.
- Maturity: The notes mature one month after issuance (February 6, 2026).
- Prepayment: The Company may prepay the notes without penalty or premium.
- Equity Inducement: Investors received warrants to purchase up to 350,000 shares of common stock at an initial exercise price of $1.00 per share.
- Use of Proceeds: Proceeds are designated for working capital and general corporate purposes.
- Liquidity and Margins: The filing text does not provide specific values for revenue, profit, cash flow, or operating margins.
Material Changes
The primary material change disclosed is the correction of dates in the original filing. The execution date of the Securities Purchase Agreements and the closing date of the transaction were originally misstated and are now corrected to January 6, 2026. The corrected forms of the Note, Warrant, and Securities Purchase Agreement supersede the exhibits in the original report.
Outlook, Risks, and Contingencies
The filing does not contain forward-looking guidance, management commentary on future performance, or specific risk factors beyond the standard terms of the debt and warrant agreements. The warrants are exercisable immediately and expire five years from issuance or upon a fundamental transaction or liquidation event. The securities were sold in reliance on exemptions from registration under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D.
Investor Verification Checklist
- Verify the corrected execution and closing date of January 6, 2026, in the amended exhibits (4.1, 4.2, and 10.1).
- Confirm the total dilution impact of the 350,000 warrant shares against the current outstanding share count.
- Assess the Company's ability to repay the $350,000 principal plus accrued interest within the one-month maturity window.
- Review the specific terms regarding adjustments to the warrant exercise price in the event of stock splits or reclassifications.